ANI Pharmaceuticals, Inc. (“ANI”) (NASDAQ: ANIP) today announced that it has acquired the new drug applications (“NDAs”) for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application (“ANDA”) for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals. Collectively, these products generated net revenues of $13.2 million in 2020. The acquisition was funded through borrowings under the Company’s pre-existing revolver credit facility.
In conjunction with the acquisition, ANI and Sandoz have entered into a multi-year manufacturing and supply agreement for OXISTAT® Lotion, Pandel® Cream, and ApexiCon® E Cream. ANI intends to transfer the manufacture and packaging of these three products to its own manufacturing sites in the future.
“This acquisition is in line with our strategy to expand our established brands business through accretive deals. Importantly, ANI will ensure that patients in need continue to receive these high-quality dermatology products. The acquisition leverages our innovative brand commercialization infrastructure and our North American manufacturing footprint,” stated Nikhil Lalwani, President, and CEO.
The Company previously shared the four pillars of its strategy for delivering sustainable future growth:
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Build a successful Cortrophin franchise;
Strengthen the Generics business by enhancing development capabilities and increased focus on niche opportunities;
Maximize the value from established brands through programmatic business development and innovative access and go-to-market strategies; and
Expand CDMO business leveraging unique North American-based manufacturing capabilities.
Source: Biospace
